Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

被引：0
|
作者：
Mathilde Bureau
Thierry Chatellier
Tanguy Perennec
Thomas Goronflot
Charlotte Greilsamer
Anne-Laure Chene
Raafet Affi
Eric Frampas
Jaafar Bennouna
Elvire Pons-Tostivint
机构：
[1] University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de Nantes
[2] Medical Oncology Unit,Department of Radiation Oncology
[3] Institut de Cancerologie de L’Ouest,INSERM
[4] University Hospital of Nantes,Pneumology Unit
[5] Medical Oncology Unit,Radiology Unit
[6] University Hospital of Nantes,undefined
[7] University Hospital of Nantes,undefined
[8] INSERM,undefined
[9] CRCINA,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Baseline tumour size; Non-small cell lung cancer; Immune checkpoint inhibitor; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1747 / 1756
页数：9
相关论文
共 50 条
  • [1] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
    Bureau, Mathilde
    Chatellier, Thierry
    Perennec, Tanguy
    Goronflot, Thomas
    Greilsamer, Charlotte
    Chene, Anne-Laure
    Affi, Raafet
    Frampas, Eric
    Bennouna, Jaafar
    Pons-Tostivint, Elvire
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1747 - 1756
  • [2] Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab
    Svaton, Martin
    Knetki-Wroblewska, Magdalena
    Tabor, Sylwia
    Domecky, Petr
    Venclicek, Ondrej
    Krejci, Jana
    Drosslerova, Marie
    Hrnciarik, Michal
    Hricisak, Daniel
    Bejckova, Alzbeta
    Fischer, Ondrej
    Vitkova, Martina
    Krzakowski, Maciej
    IN VIVO, 2024, 38 (05): : 2434 - 2440
  • [3] First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
    Amrane, Karim
    Geier, Margaux
    Corre, Romain
    Lena, Herve
    Leveiller, Guillaume
    Gadby, Florence
    Lamy, Regine
    Bizec, Jean-Louis
    Goarant, Eric
    Robinet, Gilles
    Gouva, Sylvie
    Quere, Gilles
    Abgral, Ronan
    Schick, Ulrike
    Bernier, Cyril
    Chouaid, Christos
    Descourt, Renaud
    CANCER MEDICINE, 2020, 9 (07): : 2309 - 2316
  • [4] Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer
    Imai, Hisao
    Kishikawa, Takayuki
    Minemura, Hiroyuki
    Yamada, Yutaka
    Ibe, Tatsuya
    Yamaguchi, Ou
    Mouri, Atsuto
    Hamamoto, Yoichiro
    Kanazawa, Kenya
    Kasai, Takashi
    Kaira, Kyoichi
    Kaburagi, Takayuki
    Minato, Koichi
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    CANCER MEDICINE, 2021, 10 (20): : 6971 - 6984
  • [5] First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%
    Descourt, Renaud
    Chouaid, Christos
    Perol, Maurice
    Besse, Benjamin
    Greillier, Laurent
    Bylicki, Olivier
    Ricordel, Charles
    Guisier, Florian
    Gervais, Radj
    Schott, Roland
    Auliac, Jean-Bernard
    Robinet, Gilles
    Decroisette, Chantal
    FUTURE ONCOLOGY, 2021, 17 (23) : 3007 - 3016
  • [6] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [7] Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab
    Yamaguchi, Ou
    Kaira, Kyoichi
    Shinomiya, Shun
    Mouri, Atsuto
    Hashimoto, Kosuke
    Shiono, Ayako
    Miura, Yu
    Akagami, Tomoe
    Imai, Hisao
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    THORACIC CANCER, 2021, 12 (03) : 304 - 313
  • [8] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
  • [9] Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy
    Imai, Hisao
    Kishikawa, Takayuki
    Minemura, Hiroyuki
    Yamada, Yutaka
    Ibe, Tatsuya
    Mori, Keita
    Yamaguchi, Ou
    Mouri, Atsuto
    Hamamoto, Yoichiro
    Kanazawa, Kenya
    Kasai, Takashi
    Kaira, Kyoichi
    Kaburagi, Takayuki
    Minato, Koichi
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    ONCOLOGY, 2021, 99 (09) : 562 - 570
  • [10] The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
    Banna, G. L.
    Cortellini, A.
    Cortinovis, D. L.
    Tiseo, M.
    Aerts, J. G. J., V
    Barbieri, F.
    Giusti, R.
    Bria, E.
    Grossi, F.
    Pizzutilo, P.
    Berardi, R.
    Morabito, A.
    Genova, C.
    Mazzoni, F.
    Di Noia, V
    Signorelli, D.
    Gelibter, A.
    Macerelli, M.
    Rastelli, F.
    Chiari, R.
    Rocco, D.
    Gori, S.
    De Tursi, M.
    Di Marino, P.
    Mansueto, G.
    Zoratto, F.
    Filetti, M.
    Montrone, M.
    Citarella, F.
    Marco, R.
    Cantini, L.
    Nigro, O.
    D'Argento, E.
    Buti, S.
    Minuti, G.
    Landi, L.
    Guaitoli, G.
    Lo Russo, G.
    De Toma, A.
    Donisi, C.
    Friedlaender, A.
    De Giglio, A.
    Metro, G.
    Porzio, G.
    Ficorella, C.
    Addeo, A.
    ESMO OPEN, 2021, 6 (02)
12345